Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals

Stijn P. Andeweg; Harry Vennema; Irene Veldhuijzen; Naomi Smorenburg; Dennis Schmitz; Florian Zwagemaker; Arianne B. Van Gageldonk-Lafeber; Susan J.M. Hahne; Chantal Reusken; Mirjam J. Knol; Dirk Eggink; Janke Schinkel; Matthijs R.A. Welkers; Marcel Jonges; Jelle Koopsen; Menno D.de Jong; Richard Molenkamp; David F. Nieuwenhuijse; Reina S. Sikkema; Bas B.Oude Munnink; Marion Koopmans; Adri van der Zanden; Laura Manrho; Jessica de Beer; Stefan A. Boers; Erin Meijers; Tom Vreeswijk; Igor A. Sidorov; Djoo Dunk; Pieter W. Smit; Suzan D. Pas; Jaco J. Verweij; Joep J.J.M. Stohr; Jozef Dingemans; Brian van der Veer; Lieke van Alphen; Paul Savelkoul; Hubert G.M. Niesters; Erley F.Lizarazo Forero; Monika A. Fliss; Lilli Gard; Anniek A.N. Tanja; Rob Schuurman10; Annemarie M.J. Wensing; L. Marije Hofstra; Jordy P.M. Coolen; Janette C. Rahamat-Langendoen1; Willem J.G. Melchers; Heiman F.L. Wertheim; Remco Dijkman; RIVM COVID-19 Molecular epidemiology group; SeqNeth Molecular surveillance group

doi:10.1126/scitranslmed.abn4338

Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals

Stijn P. Andeweg
, Harry Vennema
, Irene Veldhuijzen
, Naomi Smorenburg
, Dennis Schmitz
, Florian Zwagemaker
, Arianne B. Van Gageldonk-Lafeber
, Susan J.M. Hahne
, Chantal Reusken
, Mirjam J. Knol^*
, Dirk Eggink^*
, Janke Schinkel
, Matthijs R.A. Welkers
, Marcel Jonges
, Jelle Koopsen
, Menno D.de Jong
, Richard Molenkamp
, David F. Nieuwenhuijse
, Reina S. Sikkema
, Bas B.Oude Munnink

Marion Koopmans, Adri van der Zanden, Laura Manrho, Jessica de Beer, Stefan A. Boers, Erin Meijers, Tom Vreeswijk, Igor A. Sidorov, Djoo Dunk, Pieter W. Smit, Suzan D. Pas, Jaco J. Verweij, Joep J.J.M. Stohr, Jozef Dingemans, Brian van der Veer, Lieke van Alphen, Paul Savelkoul, Hubert G.M. Niesters, Erley F.Lizarazo Forero, Monika A. Fliss, Lilli Gard, Anniek A.N. Tanja, Rob Schuurman10, Annemarie M.J. Wensing, L. Marije Hofstra, Jordy P.M. Coolen, Janette C. Rahamat-Langendoen1, Willem J.G. Melchers, Heiman F.L. Wertheim, Remco Dijkman, RIVM COVID-19 Molecular epidemiology group, SeqNeth Molecular surveillance group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with =60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.

Original language	English
Article number	abn4338
Number of pages	8
Journal	Science Translational Medicine
Volume	15
Issue number	684
DOIs	https://doi.org/10.1126/scitranslmed.abn4338
Publication status	Published - 22 Feb 2023

Access to Document

10.1126/scitranslmed.abn4338Licence: CC BY

Cite this

Andeweg, S. P., Vennema, H., Veldhuijzen, I., Smorenburg, N., Schmitz, D., Zwagemaker, F., Van Gageldonk-Lafeber, A. B., Hahne, S. J. M., Reusken, C., Knol, M. J., Eggink, D., Schinkel, J., Welkers, M. R. A., Jonges, M., Koopsen, J., Jong, M. D. D., Molenkamp, R., Nieuwenhuijse, D. F., Sikkema, R. S., ... SeqNeth Molecular surveillance group (2023). Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals. Science Translational Medicine, 15(684), Article abn4338. https://doi.org/10.1126/scitranslmed.abn4338

@article{2786ef30167645a698215e1fc4743b1a,

title = "Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals",

abstract = "The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with =60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.",

author = "Andeweg, \{Stijn P.\} and Harry Vennema and Irene Veldhuijzen and Naomi Smorenburg and Dennis Schmitz and Florian Zwagemaker and \{Van Gageldonk-Lafeber\}, \{Arianne B.\} and Hahne, \{Susan J.M.\} and Chantal Reusken and Knol, \{Mirjam J.\} and Dirk Eggink and Janke Schinkel and Welkers, \{Matthijs R.A.\} and Marcel Jonges and Jelle Koopsen and Jong, \{Menno D.de\} and Richard Molenkamp and Nieuwenhuijse, \{David F.\} and Sikkema, \{Reina S.\} and Munnink, \{Bas B.Oude\} and Marion Koopmans and \{van der Zanden\}, Adri and Laura Manrho and Beer, \{Jessica de\} and Boers, \{Stefan A.\} and Erin Meijers and Tom Vreeswijk and Sidorov, \{Igor A.\} and Djoo Dunk and Smit, \{Pieter W.\} and Pas, \{Suzan D.\} and Verweij, \{Jaco J.\} and Stohr, \{Joep J.J.M.\} and Jozef Dingemans and Veer, \{Brian van der\} and Alphen, \{Lieke van\} and Paul Savelkoul and Niesters, \{Hubert G.M.\} and Forero, \{Erley F.Lizarazo\} and Fliss, \{Monika A.\} and Lilli Gard and Tanja, \{Anniek A.N.\} and Rob Schuurman10 and Wensing, \{Annemarie M.J.\} and Hofstra, \{L. Marije\} and Coolen, \{Jordy P.M.\} and Rahamat-Langendoen1, \{Janette C.\} and Melchers, \{Willem J.G.\} and Wertheim, \{Heiman F.L.\} and Remco Dijkman and \{RIVM COVID-19 Molecular epidemiology group\} and \{SeqNeth Molecular surveillance group\}",

year = "2023",

month = feb,

day = "22",

doi = "10.1126/scitranslmed.abn4338",

language = "English",

volume = "15",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "684",

}

Andeweg, SP, Vennema, H, Veldhuijzen, I, Smorenburg, N, Schmitz, D, Zwagemaker, F, Van Gageldonk-Lafeber, AB, Hahne, SJM, Reusken, C, Knol, MJ, Eggink, D, Schinkel, J, Welkers, MRA, Jonges, M, Koopsen, J, Jong, MDD, Molenkamp, R, Nieuwenhuijse, DF, Sikkema, RS, Munnink, BBO, Koopmans, M, van der Zanden, A, Manrho, L, Beer, JD, Boers, SA, Meijers, E, Vreeswijk, T, Sidorov, IA, Dunk, D, Smit, PW, Pas, SD, Verweij, JJ, Stohr, JJJM, Dingemans, J, Veer, BVD, Alphen, LV , Savelkoul, P, Niesters, HGM, Forero, EFL, Fliss, MA, Gard, L, Tanja, AAN, Schuurman10, R, Wensing, AMJ, Hofstra, LM, Coolen, JPM, Rahamat-Langendoen1, JC, Melchers, WJG, Wertheim, HFL, Dijkman, R, RIVM COVID-19 Molecular epidemiology group & SeqNeth Molecular surveillance group 2023, 'Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals', Science Translational Medicine, vol. 15, no. 684, abn4338. https://doi.org/10.1126/scitranslmed.abn4338

TY - JOUR

T1 - Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals

AU - Andeweg, Stijn P.

AU - Vennema, Harry

AU - Veldhuijzen, Irene

AU - Smorenburg, Naomi

AU - Schmitz, Dennis

AU - Zwagemaker, Florian

AU - Van Gageldonk-Lafeber, Arianne B.

AU - Hahne, Susan J.M.

AU - Reusken, Chantal

AU - Knol, Mirjam J.

AU - Eggink, Dirk

AU - Schinkel, Janke

AU - Welkers, Matthijs R.A.

AU - Jonges, Marcel

AU - Koopsen, Jelle

AU - Jong, Menno D.de

AU - Molenkamp, Richard

AU - Nieuwenhuijse, David F.

AU - Sikkema, Reina S.

AU - Munnink, Bas B.Oude

AU - Koopmans, Marion

AU - van der Zanden, Adri

AU - Manrho, Laura

AU - Beer, Jessica de

AU - Boers, Stefan A.

AU - Meijers, Erin

AU - Vreeswijk, Tom

AU - Sidorov, Igor A.

AU - Dunk, Djoo

AU - Smit, Pieter W.

AU - Pas, Suzan D.

AU - Verweij, Jaco J.

AU - Stohr, Joep J.J.M.

AU - Dingemans, Jozef

AU - Veer, Brian van der

AU - Alphen, Lieke van

AU - Savelkoul, Paul

AU - Niesters, Hubert G.M.

AU - Forero, Erley F.Lizarazo

AU - Fliss, Monika A.

AU - Gard, Lilli

AU - Tanja, Anniek A.N.

AU - Schuurman10, Rob

AU - Wensing, Annemarie M.J.

AU - Hofstra, L. Marije

AU - Coolen, Jordy P.M.

AU - Rahamat-Langendoen1, Janette C.

AU - Melchers, Willem J.G.

AU - Wertheim, Heiman F.L.

AU - Dijkman, Remco

AU - RIVM COVID-19 Molecular epidemiology group

AU - SeqNeth Molecular surveillance group

PY - 2023/2/22

Y1 - 2023/2/22

N2 - The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with =60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.

AB - The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with =60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.

U2 - 10.1126/scitranslmed.abn4338

DO - 10.1126/scitranslmed.abn4338

M3 - Article

C2 - 35862508

SN - 1946-6234

VL - 15

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 684

M1 - abn4338

ER -

Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals

Abstract

Access to Document

Fingerprint

Cite this